Three Months Ended

Six Months Ended

June 30,

(in thousands)

2026

2025

2026

2025

Operating expenses:

Research and development: Firmonertinib (excluding personnel-related and other internal costs):

FURTHER

$

1,612

$

2,848

$

3,350

$

5,443

FAVOUR

96

71

427

73

Phase 3 Trials

14,792

9,790

23,922

19,235

Other Firmonertinib costs

1,447

3,773

5,331

6,034

Total Firmonertinib

17,947

16,482

33,030

30,785

Research and development: Early-stage programs

13,383

3,625

25,690

44,606

Research and development: Personnel-related and other internal costs

11,009

7,612

21,237

13,617

General and administrative: Personnel-related costs

6,590

3,461

12,773

6,792

General and administrative: Other costs

3,762

2,443

6,071

4,594

Other segment items (a)

(2,798)

(2,224)

(5,588)

(4,609)

Net loss

$

49,893

$

31,399

$

93,213

$

95,786